COVID-19 Vaccine Response in Sickle Cell Disease

CompletedOBSERVATIONAL
Enrollment

59

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Sickle Cell DiseaseCOVID-19
Interventions
BIOLOGICAL

COVID-19 Vaccine

Vaccination against SARS-CoV-2 administered as part of standard of care

Trial Locations (8)

10467

Montefiore Hospital, The Bronx

20010

Children's National Medical Center, Washington D.C.

21205

Johns Hopkins University, Baltimore

27710

Duke University Medical Center, Durham

29601

Prisma Health - Upstate, Greenville

53226

Medical College of Wisconsin, Milwaukee

75390

University of Texas Southwestern Medical Center, Dallas

94609

UCSF Benioff Children's Hospital Oakland, Oakland

Sponsors
All Listed Sponsors
collaborator

American Society of Hematology

OTHER

collaborator

University of Pennsylvania

OTHER

lead

ASH Research Collaborative

OTHER